Skip to main content

Advertisement

SpringerLink
Log in

Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behçet uveitis

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

Our aim was to investigate whether major histocompatibility complex (MHC) polymorphisms are associated with response to infliximab therapy in Japanese patients with Behçet uveitis (BU).

Methods

We retrospectively reviewed 24 patients (17 men and seven women) treated with infliximab for BU. Of them, ten patients were genotyped as HLA A*2601, and nine as HLA B*5101. Therapeutic response levels in the two groups were compared based on ocular attacks and the Behçet disease ocular attack score 24 (BOS24) over 24 months of treatment.

Results

Mean frequencies of ocular attacks at 13–18 and 19–24 months after the start of treatment were significantly higher in the HLA A*2601 group (P = 0.0392 and 0.0177, respectively). Mean BOS24-6 M values for months 1–6, 7–12, 13–18, and 19–24 were also significantly higher in the HLA A*2601 group (P = 0.0459, 0.0150, 0.0394, and 0.0178, respectively). Shortening of the infusion interval was required in eight patients in the HLA A*2601 group but in one only in the HLA B*5101 group. Behçet-disease-related adverse events occurred in eight patients in the HLA A*2601 group and two in the HLA B*5101 group. Nonocular adverse events occurred in four patients in the HLA A*2601 group and none in the HLA B*5101 group.

Conclusions

Although mean change from baseline in the number of ocular attack scores in the HLA A26 and HLA B51 groups seemed to be similar, the HLA-A26 group had a more severe disease course under infliximab therapy for ocular/extraocular involvement. These data suggest that response to infliximab therapy in Japanese patients with BU is partly due to genetic determinants in the HLA complex.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Behçet H. Über rezidivierende aphthose, durch ein Virus verusachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr. 1937;105:1152–7.

    Google Scholar 

  2. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behçet’s disease. Arch Ophthalmol. 1982;100:1455–8.

    Article  CAS  PubMed  Google Scholar 

  3. Mizuki N, Ohno S, Ando H, Sato T, Imanishi T, Gojobori T, et al. A strong association between HLA-B*5101 and Behçet’s disease in Greek patients. Tissue Antigens. 1997;50:57–60.

    Article  CAS  PubMed  Google Scholar 

  4. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42:703–6.

    Article  CAS  PubMed  Google Scholar 

  5. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42:698–702.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Chung YM, Yeh TS, Sheu MM, Chen MS, Wen MS, Tsai HY, et al. Behcet’s disease with ocular involvement in Taiwan: a joint survey of six major ophthalmological departments. J Formos Med Assoc. 1990;89:413–7.

    CAS  PubMed  Google Scholar 

  7. Mizuki N, Ohno S, Ando H, Chen L, Palimeris GD, Stavropoulos-Ghiokas E, et al. A strong association between HLA-B*5101 and Behçet’s disease in Greek patients. Tissue Antigens. 1997;50:57–60.

    Article  CAS  PubMed  Google Scholar 

  8. Itoh Y, Inoko H, Kulski JK, Sasaki S, Meguro A, Takiyama N, et al. Four-digit allele genotyping of the HLA-A and HLA-B genes in Japanese patients with Behcet’s disease by a PCR-SSOP Luminex method. Tissue Antigens. 2006;67:390–4.

    Article  CAS  PubMed  Google Scholar 

  9. Kaburaki T, Takamoto M, Numaga J, Kawashima H, Araie M, Ohnogi Y, et al. Genetic association of HLA-A*2601 with ocular Behçet’s disease in Japanese patients. Clin Exp Rheumatol. 2010;28:S39–44.

    PubMed  Google Scholar 

  10. Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, et al. Cytokine production profile in patients with Behcet’s disease treated with infliximab. Cytokine. 2003;24:210–8.

    Article  CAS  PubMed  Google Scholar 

  11. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–8.

    CAS  PubMed  Google Scholar 

  12. Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behcet’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–8.

    Article  CAS  PubMed  Google Scholar 

  13. Behçet’s Disease Research Committee of Japan. Behçet’s disease: guide to diagnosis of Behçet’s disease. Jpn J Ophthalmol. 1974;18:291–4.

    Google Scholar 

  14. Mizushima Y. Recent research into Behçet’s disease in Japan. Int J Tissue React. 1988;10:59–65.

    CAS  PubMed  Google Scholar 

  15. Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, Ocular Behçet Disease Research Group of Japan, et al. Behçet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120–30.

    Article  CAS  PubMed  Google Scholar 

  16. Kawazoe Y, Sugita S, Yamada Y, Akino A, Miura K, Mochizuki M. Psoriasis triggered by infliximab in a patient with Behçet’s disease. Jpn J Ophthalmol. 2013;57:95–7.

    Article  PubMed  Google Scholar 

  17. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol. 2005;140:509–16.

    Article  PubMed  Google Scholar 

  18. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–71.

    Article  CAS  PubMed  Google Scholar 

  19. Lobashevsky A, Senkbeil R, Townsend J, Mink CA, Thomas JM. HLA-A, B, DR loci molecular typing using fluorescence PCR-SSO luminex methodology. Hum Immunol. 2002;63:s91.

    Article  Google Scholar 

  20. Itoh Y, Mizuki N, Shimada T, Azuma F, Itakura M, Kashiwase K, et al. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics. 2005;57:717–29.

    Article  CAS  PubMed  Google Scholar 

  21. Sayer D, Whidborne R, Brestovac B, Trimboli F, Witt C, Christiansen F. HLA-DRB1 DNA sequencing based typing: an approach suitable for high throughput typing including unrelated bone marrow registry donors. Tissue Antigens. 2001;57:46–54.

    Article  CAS  PubMed  Google Scholar 

  22. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–8.

    CAS  PubMed  Google Scholar 

  23. Hayashi N, Kawamoto T, Mukai M, Morinobu A, Koshiba M, Kondo S, et al. Detection of antinuclear antibodies by use of an enzyme immunoassay with nuclear HEp-2 cell extract and recombinant antigens: comparison with immunofluorescence assay in 307 patients. Clin Chem. 2001;47:1649–59.

    CAS  PubMed  Google Scholar 

  24. Martinez A, Salido M, Bonilla G, Pascual-Salcedo D, Fernandez-Arquero M, de Miguel S, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum. 2004;50:1077–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

K. Kuroyanagi, None; T. Sakai, None; H. Kohno, None; K. Okano, None; G. Akiyama, None; R. Aoyagi, None; M. Inaba, None; H. Tsuneoka, None.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan

    Kana Kuroyanagi, Tsutomu Sakai, Hideo Kohno, Kiichiro Okano, Goichi Akiyama, Ranko Aoyagi, Mayumi Inaba & Hiroshi Tsuneoka

Authors
  1. Kana Kuroyanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsutomu Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideo Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kiichiro Okano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Goichi Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ranko Aoyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mayumi Inaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroshi Tsuneoka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsutomu Sakai.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuroyanagi, K., Sakai, T., Kohno, H. et al. Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behçet uveitis. Jpn J Ophthalmol 59, 401–408 (2015). https://doi.org/10.1007/s10384-015-0404-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-015-0404-2

Keywords

Search

Navigation